Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Viral Hepatitis
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
Related Questions
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
What is your approach to managing concurrent severe SIADH and large-volume malignant ascites when aggressive volume removal appears to exacerbate both symptoms and hyponatremia?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
What is your endoscopic approach to the management of refractory GAVE in persistently anemic patients?
How do you utilize urine sodium and potassium levels and ratios in diuretic optimization in patients with ascites?
